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Abstract 
 
The identification of hypothermia as the cause of death remains challenging in forensic pathology 
because of unspecific radiological, morphological, and biochemical results. Hyperaemia, oedema, and 
petechial haemorrhages within the cerebral parenchyma were described in cases of death by 
hypothermia. On the other hand, the effect of low temperatures in the brain has been speculated to 
cause local injuries on a cellular level with potential occurrences of necrosis, and inflammation. In the 
study herein described, endocan, alkaline phosphatase, neuronal specific enolase, S100 protein 
subunit B, glial fibrillary acidic protein, and C-reactive protein were measured in postmortem serum 
from femoral blood and cerebrospinal fluid in a series of hypothermia fatalities and control cases. The 
combination of data collected failed to identify a specific biochemical profile for death by hypothermia 
in postmortem serum and/or the cerebrospinal fluid, thus suggesting that an alternative panel of brain 
damage biomarkers indicative of diffuse hypoxic brain injury need to be defined in hypothermia 
fatalities. 
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Introduction 
 
Hypothermia is a condition characterized by a decrease in body temperature to below 35 degrees and 
occurs when the loss of heat within an organism is greater than its production (1). 
Potentially fatal hypothermia develops insidiously and compromises numerous physiological 
functions, including neuromuscular, cardiovascular, and respiratory functions. The onset of 
hypothermia is typically accompanied by neurological symptoms such as hampered speech, lethargy, 
potential convulsions, ataxia, loss of coordination, and other changes including drowsiness, confusion, 
and unconsciousness (usually when body temperature has dropped below 30 degrees), which can 
further progress towards coma and death (2–4). 
In the realm of forensic pathology, injuries such as cerebral hyperaemia, cerebral oedema, and 
petechial haemorrhages, or so called cold-induced purpura, have been described in some cases of 
death by hypothermia, for instance in the area of the third ventricle. Moreover, haemorrhagic 
suffusions of the cerebral parenchyma have been observed by a few authors in cases of fatal 
hypothermia and have been associated with the increase in blood pressure in the cerebral arteries due 
to enhanced catecholamine secretion caused by cold exposure (5).   
Based on both the characteristics of the neurologic clinical picture of developing hypothermia and the 
postmortem morphological changes described over the course of time by various authors in cases of 
lethal hypothermia, the question arises as to whether the establishment of the (lethal) hypothermic 
process, from the initial phases to the most advanced ones, could result in neuro-morphological and 
neuro-biochemical changes, the latter analysable through targeted laboratory analyses in postmortem 
serum and cerebrospinal fluid (CSF).  
Hence, the aim of this study was to measure the concentrations of a series of molecules contained in 
(or expressed by) vascular endothelial cells, glial cells, and neuronal cells in physiological conditions in 
biological fluids collected at autopsy (postmortem serum from femoral blood and CSF) in a series of 
hypothermia fatalities and control cases, in order to assess the possible usefulness of their 
measurement for the postmortem diagnosis of antemortem cold exposure.  
These molecules included endocan, alkaline phosphatase (ALP), neuronal specific enolase (NSE), S100 
protein subunit B (S100B), glial fibrillary acidic protein (GFAP), and C-reactive protein (CRP). 
      
 
Some of these molecules have already been topics of study in the clinical setting in situations of 
neurological interest (traumatic brain injuries, brain tumours, strokes, etc.), as well as in the forensic 
setting in the postmortem serum and/or CSF in various circumstances of forensic interest (i.e. 
traumatic brain injury), but never in studies specific and exclusive to cases of lethal hypothermia (6–
27).  
 
Materials and methods 
 
Study design and study populations 
 
The present study was performed during the period 2016-2018. A total of 60 forensic autopsy cases 
(42 males and 18 females) with a mean age of 51.2 years (range 21-79) were selected and two study 
groups (hypothermia cases and control cases) prospectively identified. All cases included in the study 
originated from forensic pathology practice and underwent forensic investigations as requested by 
local inquiring authorities. 
 
The first study group consisted of 30 hypothermia fatalities (24 males and 6 females).  
The postmortem intervals for these cases was defined as the time elapsed between body discovery 
and specimen collection and ranged from 4 h to 72 h. The most relevant inclusion criteria consisted of:  
 
- hypothermia as the cause of death, 
- postmortem serum and CSF availability at autopsy, 
- exclusion of traumatic brain injury as the cause of death (exclusion of intracranial and 
intracerebral bleeding, exclusion of cortical contusion, exclusion of cortical and cerebral tissue 
damage). 
 
The cause of death was attributed to hypothermia (death following cold exposure) based on these 
inclusion and exclusion criteria: 
  
- circumstantial elements suggesting antemortem exposure to low temperatures, with no 
rewarming between exposure and death, 
- macroscopic and microscopic findings suggesting exposure to low temperatures, according to 
the available forensic literature, 
- postmortem biochemical investigation results consistent with the hypothesis of exposure to 
low temperatures, according to the available forensic literature (increased urinary 
catecholamines and metanephrines, increased blood ketones, increased urinary and 
postmortem serum cortisol), 
- exclusion of other causes of death based on all postmortem investigation findings, including 
negative toxicology. 
 
The second study group (non-hypothermia control group) consisted of 30 forensic autopsies including 
15 cases characterized by a short survival time (or short agony, defined as a period of a few seconds 
up to a few minutes, including 10 cases of witnessed sudden cardiac death with acute coronary 
thrombosis at postmortem examination and 5 cases of hanging) and 15 cases characterized by a long 
survival time (or long agony, defined as a period lasting from a few minutes up to hours). This latter 
subgroup included cases of drug intoxication only. 
Non-hypothermia control individuals including traumatic brain injury cases could not be included in 
the study due to possible CSF contamination with blood. 
As stated above, all subjects included in the non-hypothermia control group originated from forensic 
practice and underwent forensic investigations between 12 and 48 h after death. The most relevant 
inclusion criteria consisted of:  
 
      
 
- postmortem serum and CSF availability at autopsy, 
- exclusion of traumatic brain injury as the main or contributory cause of death (exclusion of 
intracranial and intracerebral bleeding, exclusion of cortical contusion, exclusion of cortical 
and cerebral tissue damage), 
- exclusion of hypothermia as the main or contributory cause of death. 
 
Deaths caused by diabetic ketoacidosis, sepsis and liver disease (as the main or contributory causes of 
death) were excluded in order to avoid central causes of hypothermia and possible interfering 
laboratory results. 
 
Sample collection 
 
Femoral blood samples were collected prior to autopsy by aspiration with sterile needles and syringes 
from the femoral vein(s). Femoral blood samples were stored in preservative-free gel and clot activator 
tubes. These were centrifuged immediately post collection at 3000 g for 15 min. After centrifugation, 
the separated supernatant (postmortem serum) was collected and stored in preservative-free tubes. 
These were transferred to the laboratories immediately post collection.  
Undiluted cerebrospinal fluid samples were collected by aspiration using a sterile needle and syringe 
by suboccipital puncture as soon as possible upon arrival of the bodies at the morgue and prior to 
autopsy or by aspiration during autopsy (direct intraventricular puncture).  No samples were excluded 
due to blood contamination. All samples were immediately centrifuged at 3000 g for 15 min. After 
centrifugation, the separated supernatant was collected and stored in tubes containing sodium 
fluoride and preservative-free tubes. No specimens were excluded due to insufficient sample volume 
(minimum accepted volume: 3 ml). Cerebrospinal fluid samples were transferred to the laboratories 
immediately post collection. 
 
Laboratory assay 
 
Endocan, S100B, and GFAP concentrations were measured by enzyme-linked immunosorbent assays. 
NSE concentrations were measured using an electrochemiluminescence immunoassay.  
CRP concentrations were measured using an immunoturbidimetric method. 
ALP concentrations were determined by standard procedures (International Federation of Clinical 
Chemistry and Laboratory Medicine reference measurement procedure at 37°C) on a Roche analyser. 
 
Statistical analysis 
 
Data were analysed using GraphPad Prism software 6.0 (published by GraphPad Software, Inc., La Jolla, 
CA, USA) as a statistical unit. Endocan, ALP, NSE, S100B, GFAP, and CRP concentrations in postmortem 
serum and CSF in hypothermia-related deaths and non-hypothermia cases were compared non-
parametrically. P values less than 0.05 were considered statistically significant. Cut-off levels 
discriminating hypothermia-related deaths and non-hypothermia cases in both analysed biological 
samples were not preliminarily identified. 
 
Results 
 
Tables 1 summarizes the main results pertaining to all studied parameters measured in postmortem 
serum and CSF in hypothermia and non-hypothermia cases. 
Concerning NSE, S100B, and GFAP, the levels measured in CSF were generally higher than the 
corresponding values in postmortem serum, as already reported by other research teams in the past 
in situations of both deaths following traumatic brain injury and deaths unrelated to traumatic brain 
injury. 
      
 
Concerning ALP and CRP, conversely, the concentrations observed in postmortem serum were 
generally more elevated than those found in CSF, in whom a slight activity was nevertheless measured, 
as already reported by some authors. 
Similar endocan values were noticed in both tested biological samples. 
Generally, no difference was observed in any of the tested biomarkers in any of the sampled fluid in 
any of the studied groups. 
Analysis of the results obtained from biomarker measurements in postmortem serum and CSF did not 
reveal statistically significant differences between hypothermia-related deaths and non-hypothermia 
cases (P < 0.05 for all biomarkers in both tested samples in all studied groups). 
In addition, in the non-hypothermia group, values measured in both biological samples for each of the 
analysed markers displayed no significant differences relating to each of the tested subgroups.  
Globally considered, these results tend to suggest that, contrary to what is observed in situations of 
traumatic brain injury, death following exposure to low temperatures is not characterized by 
significant neuronal, glial, and cerebral endothelial cell injury leading to increased endocan, ALP, NSE, 
S100B, GFAP, and CRP concentrations in postmortem serum and CSF collected at autopsy.  
In other words, the reported results seem to indicate that central nervous system impairment that 
typifies the hypothermic process does not result in corresponding substantial neuro-pathological and 
neuro-biochemical changes that might be investigated through specific laboratory analyses in 
postmortem serum and CSF. 
 
(Table 1) 
 
Table 1 summarizes the main results (ranges and median) of all the studied biomarkers obtained in 
both the hypothermia and non-hypothermia groups in both tested samples. All abbreviations are 
mentioned in the text. 
 
Tested biomarker 
 
Studied 
group 
Endocan 
(ng/ml) 
ALP 
(U/l) 
NSE 
(ng/ml) 
S100B 
(ng/ml) 
GFAP 
(ng/ml) 
CRP 
(mg/l) 
Hypothermia  
postmortem serum 
(n = 30) 
< 0.200 – 0.325 
(0.264) 
170-330 
(220) 
80-250 
(150) 
95-300 
(195) 
0.20-0.50 
(0.36) 
8-15 
(9) 
Hypothermia  
CSF 
(n = 30) 
< 0.200 – 0.310 
(0.271) 
65-115 
(101) 
800-2300 
(1400) 
130-3100 
(560) 
95-160 
(132) 
3-9 
(5) 
Non-hypothermia 
postmortem serum 
(n = 30) 
< 0.200 – 0.315 
(0.255) 
185-310 
(240) 
90-240 
(160) 
100-320 
(215) 
0.15-0.55 
(0.35) 
7-18 
(9) 
Non-hypothermia 
CSF 
(n = 30)  
< 0.200 – 0.325 
(0.267) 
50-125 
(109) 
900-2100 
(1510) 
90-3300 
(600) 
80-155 
(136) 
3-10 
(6) 
 
 
Discussion 
 
Despite the notable progress made over the last few years in the medico-legal field, it is still 
cumbersome for forensic pathologists to attribute a death to the consequences of exposure to low 
temperature, whether as a principal cause or as a contributing one (28).  
It is still correct to claim a postmortem diagnosis of hypothermia as a “negative” diagnosis, or a 
diagnosis “of exclusion,” which can be formulated, conservatively, only once compatible and 
      
 
suggestive circumstantial elements have been obtained and gathered up, on one side, and, on the 
other side, radiological, morphological, toxicological, and biochemical results have been gathered, 
which are not contrary to the initial hypothesis (29).  
There is no morphological (whether it be radiological, macroscopic, or microscopic) or biochemical 
(whether it be metabolic, or metabolomic) finding that allows, at least at the current state of 
knowledge and when considered individually and decontextualized, for a categorical statement that 
“the death was a consequence of exposure to low temperature.” The most established (and most 
scientifically correct, as could be upheld in court) practice remains, therefore, the collection and 
combination of as many morphological and biochemical results as possible, which can, when examined 
as a whole, corroborate, or not contradict, the sole/prevalent/contributing role that exposure to cold 
has had (or may have had) in the pathogenesis of the death (28–30).  
Postmortem morphological data, whether they be radiological (increased aerated lung percentage), 
macroscopic (frost erythema, Wischnewsky spots within the gastric mucosa), microscopic (Armanni-
Ebstein kidney) or biochemical (increased urinary catecholamines and metanephrines, increased blood 
ketones, increased urinary and postmortem serum cortisol, increased free fatty acids in the 
postmortem serum), do not necessarily indicate with certainty that the death is the result of exposure 
to low temperatures, even if they may allow one to better direct the diagnosis, especially in cases for 
which there is suggestive circumstantial evidence, and in the absence of other causes of death 
(1,28,29,31–33). 
In the clinical setting, it has been speculated that cerebral metabolism is reduced by 6-7% for each 
degree body temperature decreases. Self-regulation mechanisms within the cerebral blood flow allow 
for the maintenance of adequate cerebral circulation, even at temperatures of approximately 25 
degrees. As temperature decreases beyond a certain point, impairments in cerebral oxygenation can 
be observed. An insufficient supply of oxygen can seem, for example, to be responsible for the 
activation of random neurons within those parts of the brain that control vision, resulting in the 
sensation of seeing “brilliant lights” (2–4). 
The effect of lowering temperatures in the brain could, furthermore, be the cause of local injuries on 
a cellular level (endothelial, neuronal, and glial), with potential occurrences of necrosis and 
inflammation. On the other hand, even though exposure to low temperatures not seems to be 
associated with changes in the permeability of the blood-brain barrier, such exposure could be 
responsible for increases in local vascular permeability nonetheless (5). 
Based on the above, the objective of this study was to evaluate whether or not endothelial, neuronal, 
and glial cell damage, which might occur during the hypothermic process, could also be responsible 
for changes in concentrations (in the postmortem serum and/or CSF) of molecules normally contained 
within these cells or expressed within their membranes as a consequence of the occurrence of local 
necrosis and/or loss of integrity in blood-brain barrier permeability, and if these changes could be 
investigated by postmortem biochemical analyses.  
Preliminary results, as shown in Table 1, have not allowed for the identification of a specific 
biochemical profile for death by hypothermia in the postmortem serum and/or the CSF. The measured 
concentrations of all the tested molecules have failed to reveal statistically significant differences 
between hypothermic and non-hypothermic cases in either the postmortem serum or CSF.  
In respect to other studies conducted within the field of forensics, which have revealed how CSF S100B 
and NSE concentrations are increased in cases of antemortem traumatic brain injuries, as compared 
to control cases without traumatic brain injuries, the negative results obtained through this study are 
probably due to the absence of “major” traumatic brain injuries (in the parenchyma and in the 
cerebrovascular structures) in the cases of lethal hypothermia considered.  
It could be speculated that, in these cases, the hypothermic process within the brain most likely occurs 
in the form of widespread hypoxic damage that gradually happens and not in the form of significant 
localized injury, hence lacking, based on the obtained results, significant neuro-pathological changes 
objectifiable from a biochemical perspective.  
This appears to be a legitimate speculation when one considers the meaning of therapeutic 
hypothermia as a protective measure for the brain in the clinical setting. 
      
 
Nevertheless, the reported data should not appear to be discouraging, and should, rather, be 
considered a first attempt at defining a cerebral “biochemical” profile of deaths due to hypothermia. 
The hypothesis concerning the existence of neuro-pathological changes, potentially capable of being 
examined through forensic biochemical analyses, remains, in our opinion, both enticing and legitimate, 
taking into consideration the typical neurological symptoms of hypothermia.  
Therefore, a “panel” of brain damage biomarkers different and alternative must still be defined, in 
order to identify molecules stable during the postmortem period, indicative of a diffuse hypoxic brain 
injury, and with changes in their concentrations in the postmortem serum and/or CSF, clearly 
distinguishable from those potentially measurable in cases of death unrelated to both cold exposure 
and antemortem traumatic brain injury. 
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